产品
编 号：F201499
分子式：C18H19Na2O8P
分子量：440.29
分子式：C18H19Na2O8P
分子量：440.29
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 168555-66-6
产品详情
生物活性：
Fosbretabulin disodium (CA 4DP) is a tubulin destabilizing agent. Fosbretabulin disodium is the Combretastatin A4 proagent that selectively targets endothelial cells, induces regression of nascent tumour neovessels, reduces tumour blood flow and causes central tumour necrosis.
体内研究：
FosbretabuLin disodium (100 mg/kg；ip) 在给药后 1 小时和 6 小时增加平均动脉血压 (MABP)，并降低大鼠的肿瘤血流量。Animal Model:Male BD9 rats (7-9 weeks) bearing the s.c. implanted P22 tumor
Dosage:100 mg/kg
Administration:A single i.p. injections
Result:Significantly raised the MABP by about 30%, and reduced the heart rate at 1 h after administration.Reduced the blood flow in the tumor.
体外研究：
FosbretabuLin disodium 抑制白血病 P-388、胰腺 BXPC-3、成神经细胞 SK-N-SH、甲状腺 SW1736、肺-NSC NCI-H460、前列腺 DU-145、咽 FADU 的生长，EC50 分别为 0.0029、0.23、0.00025、0.00061、0.00035、0.00072 和 0.00045 μg/mL。
Fosbretabulin disodium (CA 4DP) is a tubulin destabilizing agent. Fosbretabulin disodium is the Combretastatin A4 proagent that selectively targets endothelial cells, induces regression of nascent tumour neovessels, reduces tumour blood flow and causes central tumour necrosis.
体内研究：
FosbretabuLin disodium (100 mg/kg；ip) 在给药后 1 小时和 6 小时增加平均动脉血压 (MABP)，并降低大鼠的肿瘤血流量。Animal Model:Male BD9 rats (7-9 weeks) bearing the s.c. implanted P22 tumor
Dosage:100 mg/kg
Administration:A single i.p. injections
Result:Significantly raised the MABP by about 30%, and reduced the heart rate at 1 h after administration.Reduced the blood flow in the tumor.
体外研究：
FosbretabuLin disodium 抑制白血病 P-388、胰腺 BXPC-3、成神经细胞 SK-N-SH、甲状腺 SW1736、肺-NSC NCI-H460、前列腺 DU-145、咽 FADU 的生长，EC50 分别为 0.0029、0.23、0.00025、0.00061、0.00035、0.00072 和 0.00045 μg/mL。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备